ATE295895T1 - Genetischer impfstoff gegen den immunschwäche virus - Google Patents

Genetischer impfstoff gegen den immunschwäche virus

Info

Publication number
ATE295895T1
ATE295895T1 AT93908340T AT93908340T ATE295895T1 AT E295895 T1 ATE295895 T1 AT E295895T1 AT 93908340 T AT93908340 T AT 93908340T AT 93908340 T AT93908340 T AT 93908340T AT E295895 T1 ATE295895 T1 AT E295895T1
Authority
AT
Austria
Prior art keywords
virus
vaccine against
genetic vaccine
deficiency virus
immuno deficiency
Prior art date
Application number
AT93908340T
Other languages
English (en)
Inventor
Joel R Haynes
Original Assignee
Powderject Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Vaccines Inc filed Critical Powderject Vaccines Inc
Application granted granted Critical
Publication of ATE295895T1 publication Critical patent/ATE295895T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00089—Wound bandages
    • A61F2013/00187—Wound bandages insulating; warmth or cold applying
    • A61F2013/00195—Wound bandages insulating; warmth or cold applying electric warmer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00089—Wound bandages
    • A61F2013/00187—Wound bandages insulating; warmth or cold applying
    • A61F2013/002—Wound bandages insulating; warmth or cold applying with temperature control
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00089—Wound bandages
    • A61F2013/00187—Wound bandages insulating; warmth or cold applying
    • A61F2013/00204—Wound bandages insulating; warmth or cold applying insulating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00544—Plasters form or structure
    • A61F2013/00604—Multilayer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00655—Plasters adhesive
    • A61F2013/00676—Plasters adhesive hydrogel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00727—Plasters means for wound humidity control
    • A61F2013/00748—Plasters means for wound humidity control with hydrocolloids or superabsorbers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00727—Plasters means for wound humidity control
    • A61F2013/00757—Plasters means for wound humidity control with absorbent adhesives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00902—Plasters containing means
    • A61F2013/00919—Plasters containing means for physical therapy, e.g. cold or magnetic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT93908340T 1992-03-11 1993-03-10 Genetischer impfstoff gegen den immunschwäche virus ATE295895T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85018992A 1992-03-11 1992-03-11
PCT/US1993/002338 WO1993017706A1 (en) 1992-03-11 1993-03-10 Genetic vaccine for immunodeficiency viruses

Publications (1)

Publication Number Publication Date
ATE295895T1 true ATE295895T1 (de) 2005-06-15

Family

ID=25307503

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93908340T ATE295895T1 (de) 1992-03-11 1993-03-10 Genetischer impfstoff gegen den immunschwäche virus

Country Status (9)

Country Link
EP (1) EP0584348B1 (de)
JP (1) JP3881689B2 (de)
AT (1) ATE295895T1 (de)
CA (1) CA2102918C (de)
DE (1) DE69333814T2 (de)
DK (1) DK0584348T3 (de)
ES (1) ES2242954T3 (de)
PT (1) PT584348E (de)
WO (1) WO1993017706A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US7001759B1 (en) 1993-01-26 2006-02-21 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
ES2249760T3 (es) 1993-01-26 2006-04-01 The Trustees Of The University Of Pennsylvania (A Corporation Of Pennsylvania) Composiciones y procedimientos de administracion de materias geneticas.
US5981505A (en) * 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
DE69435182D1 (de) * 1993-01-26 2009-02-26 Univ Pennsylvania Zusammensetzung zur Verabreichung genetischen Materials
US5804566A (en) * 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US6348449B1 (en) 1993-09-21 2002-02-19 The Trustees Of The University Of Pennsylvania Methods of inducing mucosal immunity
ATE475668T1 (de) 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
US6995008B1 (en) 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
AT405607B (de) * 1995-05-23 1999-10-25 Immuno Ag Verbesserte vakzine zur immunisierung gegen tbe-virusinfektionen sowie ein verfahren zu dessen herstellung
HU219503B (hu) 1994-07-08 2001-04-28 Baxter Aktiengesellschaft Javított vakcina TBE-vírusfertőzés elleni immunizálásra, valamint eljárás az előállítására
US6300118B1 (en) 1995-06-07 2001-10-09 American Home Products Corporation Plasmids comprising a genetically altered feline immunodeficiency virus genome
US5820869A (en) * 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
US7223739B1 (en) 1995-06-07 2007-05-29 Powderject Vaccines, Inc. Adjuvanted genetic vaccines
US5851804A (en) * 1996-05-06 1998-12-22 Apollon, Inc. Chimeric kanamycin resistance gene
CA2257137A1 (en) 1996-06-11 1997-12-18 Merck & Co., Inc. Synthetic hepatitis c genes
JP2001503260A (ja) 1996-10-23 2001-03-13 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 改良されたワクチン
US6200959B1 (en) 1996-12-04 2001-03-13 Powerject Vaccines Inc. Genetic induction of anti-viral immune response and genetic vaccine for filovirus
US6818627B1 (en) 1997-08-14 2004-11-16 The Trustees Of The University Of Pennsylvania Functional fragments of HIV-1 Vpr protein and methods of using the same
WO1999013896A1 (en) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Attenuated vif dna immunization cassettes for genetic vaccines
US6482804B1 (en) 1997-10-28 2002-11-19 Wyeth Compositions and methods for delivery of genetic material
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
AU5366099A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
US6355271B1 (en) 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
AU779395B2 (en) 1999-04-30 2005-01-20 Institut De Recherche Cliniques De Montreal (Ircm) Mutant human CD80 and compositions for and methods of making and using the same
EP1083230A1 (de) * 1999-09-10 2001-03-14 Academisch Medisch Centrum Amsterdam Virale Replikons und von induzierenden Wirkstoffen abhängige Viren
CA2388301C (en) 1999-10-22 2011-01-04 Aventis Pasteur Limited Modified gp100 and uses thereof
EP1792995A3 (de) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia Antigene, entsprechende DNS Fragmente und ihre Verwendungen
US7851212B2 (en) 2000-05-10 2010-12-14 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
DE60131975T2 (de) 2000-07-27 2008-12-18 The Trustees Of The University Of Pennsylvania Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
WO2002100317A2 (en) 2001-05-25 2002-12-19 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
EP1500665B1 (de) 2002-04-15 2011-06-15 Chugai Seiyaku Kabushiki Kaisha VERFAHREN ZUR HERSTELLUNG VON scDb-BIBLIOTHEKEN
DE60327199D1 (de) 2002-04-26 2009-05-28 Chugai Pharmaceutical Co Ltd Verfahren zum screening auf agonistische antikörper
EP1356820A1 (de) 2002-04-26 2003-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) DNA-Impfstoff kombiniert mit einen Apoptoneauslöser von Tumorzellen
TW200407335A (en) 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
AU2003271186A1 (en) 2003-10-14 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
EP1720520B1 (de) 2004-02-13 2010-06-09 Nod Pharmaceuticals, Inc. Partikel mit kern aus calciumphosphat-nanopartikeln, biomolekül und gallensäure, herstellungsverfahren und therapeutische verwendung
US7572600B2 (en) 2004-08-04 2009-08-11 Chemocentryx, Inc. Enzymatic activities in chemokine-mediated inflammation
JP4852773B2 (ja) 2004-10-15 2012-01-11 国立大学法人三重大学 肝再生・修復制御剤
CA2586035A1 (en) 2004-11-01 2006-05-11 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles in use for aesthetic or cosmetic medicine, and methods of manufacture and use
EP2824183B1 (de) 2005-04-08 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Verfahren zur Herstellung bispezifischer Antikörper
JP2007006728A (ja) * 2005-06-28 2007-01-18 Bando Chem Ind Ltd 被覆無機粒子およびその利用
WO2008099920A1 (ja) 2007-02-15 2008-08-21 Kyushu University, National University Corporation 抗hmgb-1抗体を含む間質性肺疾患治療剤
EP2411519B1 (de) 2009-03-27 2015-07-22 Institut National de la Santé et de la Recherche Médicale Kanamycin-antisense-nucleinsäure zur behandlung von krebs
CA2798837A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
JP5315495B2 (ja) 2010-09-28 2013-10-16 積水化学工業株式会社 抗ヒトｃｃｒ７抗体、ハイブリドーマ、核酸、ベクター、細胞、医薬組成物、並びに、抗体固定化担体
CN105859889B (zh) 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
KR102190180B1 (ko) 2011-04-15 2020-12-11 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 Ｄｎａ 백신
EP2891497B1 (de) 2012-08-31 2020-07-01 Osaka University Dna-impfstoffhaltiges vegf-spezifisches epitop und/oder angiopoietin-2-spezifisches epitop
CA3130051A1 (en) 2019-02-18 2020-08-27 Nb Health Laboratory Co., Ltd. Method for selecting cells, method for producing nucleic acid, method for producing recombinant cells, method for producing target substance, method for producing pharmaceutical composition, and reagent
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
TW202220677A (zh) 2020-07-31 2022-06-01 日商中外製藥股份有限公司 含有表現嵌合受體之細胞的醫藥組成物
EP4596706A4 (de) 2022-09-30 2026-01-14 Fujifilm Corp Screening-verfahren für eine zelle, die eine zielsubstanz produziert, nukleinsäureherstellungsverfahren und zielsubstanzherstellungsverfahren
AU2023365423A1 (en) 2022-10-18 2025-03-20 Nb Health Laboratory Co., Ltd. Antibody, nucleic acid, cell, and pharmaceutical
AU2024247601A1 (en) 2023-03-28 2025-10-23 Nb Health Laboratory Co., Ltd. Antibody, nucleic acid, cell and drug
WO2024200831A1 (en) 2023-03-30 2024-10-03 Vivadju Pvax14 nucleic acid in combination with all-trans retinoic acid (atra) and a checkpoint inhibitor for the treatment of cancer
JP7784193B1 (ja) 2024-01-31 2025-12-11 株式会社エヌビィー健康研究所 抗体、核酸、細胞、及び医薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036006A (en) * 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
AU6170486A (en) * 1985-08-23 1987-02-26 Advanced Genetics Research Institute Defective viral vaccines
WO1989005349A1 (en) * 1987-12-09 1989-06-15 The Australian National University Method of combating viral infections
AU5856790A (en) * 1989-06-26 1991-01-17 Agracetus, Inc. Particle-mediated transformation of animal somatic cells
EP0500799B1 (de) * 1989-11-16 1998-01-14 Duke University Transformation von tierischen Hautzellen mit hilfe von Partikeln
US7506947B2 (en) * 2004-03-09 2009-03-24 Canon Kabushiki Kaisha Ink jet printing apparatus and method using media shape detection

Also Published As

Publication number Publication date
EP0584348B1 (de) 2005-05-18
DE69333814T2 (de) 2006-02-02
JP3881689B2 (ja) 2007-02-14
PT584348E (pt) 2005-10-31
EP0584348A4 (en) 1996-05-29
EP0584348A1 (de) 1994-03-02
DK0584348T3 (da) 2005-09-19
ES2242954T3 (es) 2005-11-16
DE69333814D1 (de) 2005-06-23
WO1993017706A1 (en) 1993-09-16
JPH06508153A (ja) 1994-09-14
CA2102918C (en) 2007-05-08
CA2102918A1 (en) 1993-09-12

Similar Documents

Publication Publication Date Title
DE69333814D1 (de) Genetischer impfstoff gegen den immunschwäche virus
DE69824013D1 (de) Impfstoff gegen hpv
PT101052A (pt) Proteinas hibridas uteis na preparacao de vacinas
DE69632235D1 (de) Newcastle-Krankheitsvirus-Kombinationsimpfstoff
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
DE69030172D1 (de) Impfstoffe gegen Krebs und Infektionskrankheiten
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
CO5070644A1 (es) Vacunas que comprenden proteinas e6 de hpv y/o e7 de hpv junto con un oligonucleotido cpg como adyudante
LU91323I2 (fr) Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé).-silgard
DK157087A (da) Multivalent vaccine, isaer herpesvirusvaccine, dens anvendelse og deri indgaaende virus
EP0755259A4 (de) CHIMÄRE cDNA-KLONE DES VIRUS DER INFEKTIÖSEN BURSAL-KRANKHEIT, EXPRESSIONSPRODUKTE UND DARAUF BASIERENDE IMPFSTOFFE
IL132468A0 (en) A kit for inducing immune response against a tumor or a disease caused by an infection agent
NO924780L (no) Ekspresjon av spesifikke immunogener ved bruk av virusantigener
ATE105334T1 (de) Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
NL300336I2 (nl) Vaccin tegen de bof dat een jeryl-lynn virusstam bevat
ATE188484T1 (de) Immunologisch mit hla homologe hiv protein epitope
ATE102650T1 (de) Mutanten des infektioesen bovinen rhinotracheitisvirus, vakzine die sie enthalten, verfahren zu ihrer herstellung und ihrer verwendung.
DE3889581D1 (de) Monoklonale Antikörper gegen spezifische antigene Regionen des humanen Immundefizienzvirus und Methoden zur Verwendung.
DE69633919D1 (de) Mehrzweckvakzine gegen umhüllte viren
FI890603A0 (fi) Menetelmä HIV-hiukkasimmunogeenin ja sen vasta-aineen valmistamiseksi
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
BR9306187A (pt) Vacina bacterin-toxóide pasteurella haemolytica tipo a-1
ATE247485T1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
SE8700466D0 (sv) Vaccines against melanoma
DE69228063D1 (de) Abgeschwächter rückmutierter virusimpfstoff gegen mareks krankheit serotyp-1

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0584348

Country of ref document: EP

REN Ceased due to non-payment of the annual fee